Abciximab

Drug Profile

Abciximab

Alternative Names: c7E3; CentoRx; Centrex; ClearWay®RX/abciximab; Monoclonal antibody 7E3; ReoPro

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Centocor
  • Developer Centocor; Eli Lilly; Janssen Biotech
  • Class Antiplatelets; Fab fragments; Ischaemic heart disorder therapies; Monoclonal antibodies
  • Mechanism of Action GPIIb-IIIa antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Coronary artery restenosis; Unstable angina pectoris
  • Discontinued Arterial occlusive disorders; Myocardial infarction; Stroke

Most Recent Events

  • 03 May 2013 Final efficacy data from the INFUSE-AMI phase III trial in Myocardial infarction (new drug delivery system) released by Atrium Medical Corporation
  • 30 Apr 2012 Launched for Coronary artery restenosis in Ireland (IV)
  • 25 Nov 2011 Launched for Coronary artery restenosis in Russia (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top